Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdf

Dynamic Offerings
Meeting the Demands
of Modern Healthcare
Prioritizing Quality
Safety and Efficacy
in the Healthcare
Industry
August
|
Issue
02
|
2023
Morpheus AG
Maximizing Safety, Efficiency and Effec veness in the
Opera ng Room through Next-Gen Medical Technology
Timo Rack
CEO
Morpheus AG
Companies of
2023
Medical
Europe’s
Most Innova ve

Be er Health and
a better way of life.

n the ever-evolving healthcare landscape, where the
Ipursuit of innovation and excellence is paramount, we
find ourselves at the threshold of a remarkable journey.
In this edition of Insights Care, we invite you to embark on
a captivating odyssey through the corridors of Europe's
Most Innovative Medical Device Companies of 2023.
In the face of unprecedented challenges, the medical device
industry has risen to the occasion with unwavering
determination. The stories we share within these pages
testify to the relentless pursuit of progress, the spirit of
innovation, and the steadfast commitment to improving
lives.
As you flip through these pages, you'll meet visionaries
who have reimagined the future of healthcare. From
advanced diagnostic tools that offer earlier and more
accurate disease detection to revolutionary surgical devices
that have transformed the precision of procedures, these
companies are shaping the course of medical history.
But innovation isn't just about cutting-edge technology; it's
also about the people behind it. Throughout this edition,
you'll encounter the brilliant minds and dedicated teams
who have poured their hearts and souls into these life-
changing creations.
The stories you'll find here are not just about products;
they're about the human spirit. They're about resilience,
inspiration, and the profound impact that innovation can
have on individuals, families, and communities.
So, dear readers, prepare to be captivated, inspired, and
transported into a world where the boundaries of possibility
are constantly pushed. Join us on this remarkable journey
through the pages of Insights Care as we celebrate Europe's
Most Innovative Medical Device Companies of 2023. It's a
tribute to the pioneers of progress and an indication of the
enduring spirit of innovation that fuels our quest for a
healthier world.
Happy reading!
-Pooja Shah
Pja Sh
The Innovation
Chronicles

CathVision
On a Mission to Help Physicians
Cure Cardiac Arrhythmia
16
24
iCellate Medical AB
Reducing Cancer Mortality Through Early
Detec on & Ac onable Cancer Proﬁling
Scandinavian
ChemoTech
The Impact of Oncology
Technology on Pa ent Care
30
The Swedish Assistive
Technology Group
Enhancing Independence for
Physical Disabili es 40
34 Safety and Eﬃcacy in the
Healthcare Industry
Mee ng the Demands of
Modern Healthcare
Dynamic Offerings
20
Articles
C
O
N
T
E
N
T
S

Morpheus
AG
Maximizing Safety, Eﬃciency
and Eﬀec veness in the
Opera ng Room through
Next-Gen Medical Technology
08
Cover
Sto

Copyright © 2023 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or
transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success.
Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Insights Care is powered by Insights Success Media and Technology Pvt. Ltd.
August, 2023
sales@insightscare.com
Follow us on : www.facebook.com/InsightsCare/ https://twitter.com/Insightscare
Contact Us:
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin, OH 43017, United States
Phone - +1614-602-4132
Email: info@insightscare.com
For Subscription: www.insightscare.com
Insights Success Media and Technology Pvt. Ltd.
Survey No.133/134, Brand Square, Ofﬁce No. 512,
Kunjir Chowk, Pimple Saudagar, Pune,
Maharashtra 411027.
Phone - India: 7410033802, 8956487823
For Subscription: www.insightscare.com
Editor-in-Chief
Chidiebere Moses Ogbodo
Managing Editor
Pooja Shah
Executive Editor
Nisha Mehra
Visualiser
David King
Art & Design Head
Mrunalinee Deshmukh
Co-designer
Paul Belin
Art & Picture Editor
Deepanjali Jena
Business Development
Manager
Emily Jones
Marketing Manager
Bill Thompson
Business Development
Executives
Anna Smith, Jack Miller
Sales Executives
Mike, Carl, John
Technical Head
Jacob Smile
Assistant Technical Head
Prashanth Hiremath
Technical Consultants
David, Robert
Digital Marketing
Manager
Alina Sege
Assistant Digital
Marketing Manager
Sagar Lahigade
SME-SMO Executives
Gemson
Research Analyst
Eric Smith
Circulation Manager
Tanaji Fartade
We are also available on :

Description
Featuring
Person
Company Name
CathVision
cathvision.com
Mads Emil
Matthiese
CEO & Co-founder
CathVision is focused on developing
electrophysiology solutions centered around an
innovative EP recording system and AI-based
analytic tools.
The Swedish Assistive
Technology Group
hjalpmedelsteknik.se
Lars Akerman
CEO
The Swedish Assistive Technology Group
has the market's largest selection of small and
large aids.
iCellate Medical AB
icellate.com
Pelle Redare
CEO
iCellate develops liquid biopsy services for
cancer detection and biomarker analysis –
enabling precision medicine.
Morpheus AG
morpheus.com.ag
Timo Rack
CEO
Morpheus AG designs and develops next
generation instruments for maximum safety,
efﬁciency and effectiveness in the operating
theatre.
Scandinavian
ChemoTech AB
chemotech.se
Mohan S Frick
CEO
Suhail Sayeed Mufti
Medical Director
Scandinavian ChemoTech AB is ChemoTech is
a R&D based company developing innovation
in the ﬁeld of oncology.
Companies of
2023
Device
Medical
Europe’s
Most Innova ve

Morpheus AG
Maximizing Safety, Efficiency and
Effec veness in the Opera ng Room through
Next-Gen Medical Technology
At Morpheus AG, we're constantly
looking for ways to improve surgical instruments
and develop new technologies that can help
healthcare professionals perform their jobs more
effec vely. We believe that by combining technical
exper se with crea ve thinking, we can bring
cu ng-edge solu ons to the medical industry
and make a real difference in
people's lives.
Cover
Story

Technology is fast changing the world for the better.
And surgical rooms are not separate from it. Today,
surgical rooms have incorporated the innovative
support of technology for attaining their core objective:
patient safety. It is known for delivering safer, more
efficient and faster surgical processes. In addition, its speed
and accuracy not only enable surgeons in conducting a
smooth surgical process but also guarantees a reduced risk
of injury.
Morpheus AG, a medical device company is dedicated to
improving patient outcomes and helping healthcare
professionals perform their jobs more efficiently through its
innovative cutting-edge technology. One of its flagship
products, for instance, the Rebellion Bone Removal
System—is a valuable tool for orthopedic surgeons—for
having the ability to cut through large amounts of hard
bone, thus minimizing the need for additional instruments
and reducing the risk of injury.
But that's not it. Timo Rack, the CEO of Morpheus AG is
committed to redefining the status quo of innovative
surgical instruments and designing next-generation
instruments for maximizing safety, efficiency and
effectiveness in the operating room. Being a leader with
such an extraordinary vision of improving the lives of
patients and physicians alike—Timo knew that the key to
success in this field was to combine technical expertise with
creative thinking. Hence, that's what Morpheus AG has
been doing ever since.
Let's dive in to learn more about the operations behind
Morpheus AG in innovating state-of-art surgical
instruments.
Morpheus AG in Brief
Morpheus AG is dedicated to developing innovative
medical devices that can improve patient outcomes and help
healthcare professionals perform their jobs more efficiently.
Its mission is to bring cutting-edge technology to the
medical industry and make a real difference in people's
lives.
One of the company's flagship products, the Rebellion Bone
Removal System, is already on the market and making a
significant impact in the field of orthopedics and
neurosurgery. The system, which uses a disposable punch
and a collector, is always sharp, ensuring optimal bone
removal with each use. The device also features an
ergonomic handle, which allows for greater precision and
control during surgery.
But that's not all. This saves OR time and money! The
system safely collects bone material, ensuring good bone
quality and vital bone cells are preserved. And of course,
safety is always its top priority. The Rebellion Bone
Removal System is supplied in a sterile condition, meaning
there's no risk of cross-contamination during surgery.
Morpheus AG is always committed to pushing the
boundaries of what's possible in medical technology.
Ensuring Safety and Effectiveness in the Operating
Theatre
Morpheus AG's Rebellion Bone Removal System, for
example, is designed to be extremely effective in cutting
through large amounts of very hard bone, making it a
valuable tool for orthopedic surgeons.
The system's multi-bite function allows the surgeon to stay
on the site with the instrument, minimizing the need for
additional instruments and reducing the risk of injury. The
system is also sterile, ensuring that there is no cross-
contamination during surgery, which is essential for
ensuring patient safety.
Europe’s Most Innova ve Medical Device Companies of 2023
We've developed our own innova on
techniques, which enable us to push the
boundaries of what's possible in medical
technology and design innova ve
instruments that meet the unique needs
of healthcare professionals. We take
great care in manufacturing our
products to the highest quality
standards, and we're proud to say that
99% of our products are made in
Germany using only the best materials
and equipment available.

"But we're not stopping there. At Morpheus AG, we're
constantly looking for ways to improve surgical instruments
and develop new technologies that can help healthcare
professionals perform their jobs more effectively. We
believe that by combining technical expertise with creative
thinking, we can bring cutting-edge solutions to the medical
industry and make a real difference in people's lives," says
Timo.
State-of-Art Surgical Instruments
In addition to designing and manufacturing innovative
surgical instruments, Morpheus AG also provides contract
designing services to other Med-Tech firms. Its engineering
team, which consists of highly skilled and creative
individuals, is dedicated to bringing the best possible
solutions to the table.
Timo emphasizes, “We've developed our own innovation
techniques, which enable us to push the boundaries of
what's possible in medical technology and design
innovative instruments that meet the unique needs of
healthcare professionals. We take great care in
manufacturing our products to the highest quality standards,
and we're proud to say that 99% of our products are made in
Germany using only the best materials and equipment
available."
"Our manufacturing process includes a well-equipped
quality assurance, metallurgy laboratory to ensure that our
products meet the highest standards of quality, safety and
effectiveness. We're ISO 13485 certified, which means that
our products have undergone rigorous testing and meet the
strictest requirements for safety and effectiveness. If you're
interested in learning more about our services or have a
need for our expertise, you are welcome to contact us."
Values and Mission
The core values at Morpheus AG are innovation, quality,
safety and effectiveness. The company is focused on
surgeons and their daily struggles. "We are here to help
them and to permanently change it with our solutions.
These values are at the heart of everything we do, and they
guide our mission to develop and manufacture innovative
surgical instruments that can improve patient outcomes and
help healthcare professionals perform their jobs more
efficiently," says Timo.

Morpheus AG's dedication to the surgeons and its
innovation is what sets it apart from other companies in the
industry. Its engineering team consists of highly skilled and
creative individuals who are dedicated to bringing the best
possible solutions to the table. The company is empowered
by its proprietary innovation techniques to design advanced
instruments that cater to the distinct requirements of
healthcare professionals.
Morpheus AG's mission is to make a real difference in
people's lives by developing and manufacturing innovative
surgical instruments that solve the daily struggles with the
status quo.
Taking Sustainable Measures
Currently, Morpheus AG is leading specific endeavors in
the area of environmental protection. As a manufacturer of
disposable medical products, it recognizes its responsibility
to minimize the environmental impact of its products. "We
believe that it's essential to take steps to protect the
"I grew up in an entrepreneurial family that has
been in the medical technology industry since
1949. With this kind of background, it was almost
natural that I would also pursue a career in this
field. Our family business specialized in contract
manufacturing of various surgical instruments,
based on customer drawings. For a while, I
enjoyed working in the business alongside my
father and helping build it up.
However, things took a turn when I received
personal coaching and later discovered through
various tests that I had above-average crea ve
abili es. This sparked my interest in medical
technology even more, and I started looking for
ways to channel my crea vity into this field. I
wanted to build a pla orm where I could bring
my ideas to life and create innova ve products
that could help improve pa ent outcomes.
My vision was to create innova ve medical
devices that could improve the lives of pa ents
and physicians alike. I knew that the key to
success in this field was to combine technical
exper se with crea ve thinking, and that's what
we've been doing at Morpheus AG ever since. I
build a team consis ng of highly skilled
engineers, designers, medical professionals, and
a small but truly experienced sales team who
share my passion for innova on. So basically, my
journey into the medical device sector was
inspired by my family's legacy, my passion for
medical technology, and my crea ve abili es."
About the CEO: In his own words
We're always open to new
opportuni es and partnerships,
and we welcome inquiries from
both sales and investors. As we
look towards the future, we remain
commi ed to developing and
manufacturing innova ve surgical
instruments that meet the highest
standards of quality, safety, and
effec veness.

environment and ensure that no healthcare professional
should feel guilty about using our products," highlights
Timo.
"To that end, we're collecting data and comparing the
environmental impact of disposable versus reusable
instruments. We're also exploring solutions to ensure that
our products can be recycled or at least offset the CO2
emissions resulting from their use. This is a crucial issue
that we take seriously, and we're committed to taking action
to minimize the environmental impact of our products," he
says.
Turning Challenges into Opportunities
Speaking of challenges, Timo highlights specific points that
are noteworthy within the industry. He says, "At Morpheus
AG, we face several challenges in conducting our
operations, particularly with the increased requirements of
the MDR. This has sadly forced many Med-Tech companies
to reevaluate our approach to innovation, prioritizing
economic viability over patient benefit. This challenge is
particularly acute in the EU market, where we fear that
innovative products may be shifted towards markets like the
US or Asia due to the stringent MDR requirements."
He then continues, "As a startup, we recognize the
importance of global presence, and this remains one of our
main strategic objectives in terms of building our
distribution networks. However, we also recognize that
there will always be changes and challenges in local
markets, which is why we believe it's important to have a
broad and diverse sales structure."
"At Morpheus AG, we see these challenges as opportunities
for growth. While we recognize that there may be obstacles
to innovation in the EU market. But we also believe that
there are still significant opportunities to develop and
market innovative products globally. By broadening our
sales network and taking a proactive approach to global
expansion, we're confident that we can overcome these
challenges and continue to grow as a company. We believe

in the power of innovation and are confident in our ability
to develop products that benefit patients and healthcare
professionals worldwide," emphasizes Timo.
Words of Wisdom
To budding entrepreneurs and enthusiasts who aspire to
engage in the medical devices sector, Timo's advice would
be to start by building a small but excellent team. He says,
"As a leader, it's essential to have a great team and good
team spirit. To lead and take care of your team invite them
to regular one-on-one talks to see how they feel and where
they are. This will help you to understand their perspectives
and keep them motivated and engaged."
"In the medical devices sector, it's also essential to stay up
to date with the latest developments and trends. Be open to
new ideas and be willing to take risks to pursue innovation.
Finally, always prioritize quality and safety in everything
you do, as these values are critical in the medical field."
Last, but not least, be grateful for leading a great and
unique team and don´t skimp on praise and appreciation for
all their great work!
I have to say it: "THANK YOU MORHEUS TEAM! You
are the BEST!"
Scaling 2023 and Beyond
Morpheus AG is currently in a phase between Early-Seed
and "Hello-VC/Private Equity-let's talk." "Looking towards
the future, we plan to scale our services and operations by
expanding our market presence and distribution network.
Our next goal is to increase our market share to over 15%,
which will require hard work and dedication. But we're
confident that we can achieve this goal and continue to
grow as a company," highlights Timo.
“We're always open to new opportunities and partnerships,
and we welcome inquiries from both sales and investors. As
we look towards the future, we remain committed to
developing and manufacturing innovative surgical
instruments that meet the highest standards of quality,
safety and effectiveness."
"We're excited about the opportunities and challenges that
lie ahead. I wish to thank you for the interview, and we
appreciate the opportunity to share our vision and mission
with your audience," he concludes.
While we recognize that
there may be obstacles to innova on
in the EU market, we also believe that
there are s ll significant opportuni es
to develop and market innova ve
products globally. By broadening our
sales network and taking a proac ve
approach to global expansion, we're
confident that we can overcome
challenges and con nue to
grow as a company.

On a Mission to Help Physicians
Cure Cardiac Arrhythmia
CathVision is
redeﬁning the necessity
of exceptional cardiac
electrical signals to
diagnose, characterize,
and treat the most
common heart rhythm
disorders.
Mads Emil Matthiesen
CEO & Co-founder
August 2023
16|www.insightscare.com

Harnessing cutting-edge technologies have
revolutionized the healthcare landscape and are
poised to redefine how we treat conditions like
cardiac arrhythmias. These innovative products and
precision-focused designs have created breakthrough
solutions to provide more effective, efficient, and safer
treatments for patients with various cardiac conditions.
Embracing the future of cardiac ablation therapy,
CathVision is playing a big part in a transformative journey
towards better health.
The team at CathVision works closely with
electrophysiologists throughout the world to fully
understand how the technology is being used to improve the
diagnosis and treatment of complex cardiac arrhythmias.
This motivation brought Insights Care to interview Mads
Emil Matthiesen, CEO & Co-founder at CathVision, to
know more about the company's ground-breaking system.
Below are the highlights of the interview:
Kindly tell us about your journey and inspiration
behind venturing into the medical device sector.
When I was a Biomedical Engineering student, I longed for
projects that allowed me to do more tangible things than
reading textbooks. On an exchange program in the US, I
was fortunate to be introduced to an electrophysiologist
who showed their electrophysiology lab for cardiac ablation
procedures. I fell in love with the abundance of technology
that these physicians used everyday to cure patients from
cardiac arrhythmia.
Brief us about the company. How is it contributing to
the existing needs of healthcare? What solution is it
bringing to the table?
More than 40 million people suffer from cardiac
arrhythmia, and most will never receive ablation treatment
despite this being one of the most effective treatment
options. And even for those that do, there is a 50% chance
of disease recurrence leading to the need for repeat ablation
procedures.
For many years, industry leaders have ignored the
importance of quality cardiac electrogram signals in the
diagnosis, characterization and treatment of cardiac
arrhythmia. Conventional EP recording systems typically
acquire noisy and artifact-ridden electrogram signals,
preventing the accurate analysis and interpretation of those
signals and severely limiting the ability of
electrophysiologists to correctly diagnose and devise
ablation strategies.
This is what CathVision is changing.
CathVision is a medical technology company that develops
electrophysiology solutions centered around an innovative
EP recording system and suite of AI algorithms – the
ECGenius System with CARDIALYTICS. Committed to
empowering physicians to make more informed clinical
decisions in the EP lab, CathVision is redefining the
necessity of exceptional cardiac electrical signals to
diagnose, characterize, and treat the most common heart
rhythm disorders.
Give us an idea about the company's services/products.
What is the process of innovating medical devices at the
company? What demographics is the company serving?
CathVision has reimagined one of the EP lab's most
traditional and stagnant pieces of technology. By
developing an EP recording system characterized by
superior signal acquisition, along with the
CARDIALYTICS suite of artificial intelligence and analytic
modules, CathVision can enrich the type of cardiac data
collected, giving physicians information for diagnosing,
characterizing and treating cardiac arrhythmias.
Can you elaborate upon the core values on which the
company is built and what is its mission?
CathVision's mission is to empower electrophysiologists to
cure arrhythmias by modernizing and enhancing the
technological capabilities of EP recording systems. We
were founded by biomedical engineers, the motivation to
develop technology for professionals to help treat patients
better is in our DNA.
Our three core values at CathVision drive every aspect of
our work:
Ÿ Collaboration: We share knowledge, we listen and we
collaborate directly with each other across functions. We
are still a relatively small entity where everyone can
know everyone, which gives a special feel for new
people joining.
Ÿ Self-management: We value that everyone is
responsible for their own and their team's goals towards
Europe's Most Innova ve Medical Device Companies of 2023
August 2023

our company goals. We foster a culture where you bring
your thoughts forward and where we are each
accountable for bringing solutions forward.
Ÿ Continuous learning: We are driven by relatively
young, entrepreneurial minds who want to learn and
grow. We practice an open mindset to evaluate issues
and setbacks, where we aim to seek feedback from each
other. We are in a technically and clinically advanced
area where everyone needs a humble attitude to keep
learning.
What role does technology play in facilitating the
innovation of medical devices at the company?
Technology is how we solve the clinical problems that are
known in the field today.
We have developed a proprietary signal amplifier that can
record a high amount of heart signals at a low noise.
Conventional amplifiers suffer from limitations in the way
they form signals, the amount of signals they take in, the
sample rate and other hardware specifications. We have 5
patent families covering low-noise inventions.
What specific endeavors is the company leading at
present? Why do you find those essential in the arena of
care?
The field of cardiology has been exploring the potential
benefits of integrating artificial intelligence into medical
devices and systems for several years. Lauded in healthcare
as early adopters, there is definitive acceptance of AI's
potential to positively impact the analyses of data that can
lead to more defined treatment and improved outcomes
specifically for cardiac arrhythmia patients. This is a key
focus area for CathVision – we're turning potential into
reality. We recently secured FDA clearance of our
ECGenius System with CARDIALYTICS – this is the first
and only EP recording system available with AI algorithms
to facilitate electrogram interpretation and deliver
unprecedented levels of intelligent, automated analyses
designed to improve ablation outcomes in complex atrial
arrhythmia procedures.
The CARDIALYTICS suite includes:
Ÿ PVI Analyzer: a signal-based AI algorithm capable of
confirming PVI isolation status across multiple cardiac
ablation modalities when physicians treat complex
arrhythmias such as atrial fibrillation.
Ÿ Signal Complexity: an algorithm to help physicians
visualize and quantify atrial fibrillation (AF) complexity
August 2023

parameters in patients
with persistent AF.
What are some of the
challenges the company
faces when conducting its
operations and how does it
turn them into growth
opportunities?
Being a start-up company in
the medtech sector comes
with many challenges; one of
the most significant obstacles
to overcome is financial.
Advancing medical
technology from idea to
commercialization requires
time and financial resources. At CathVision, we've been
fortunate to partner with a small team of committed
investors that believe in our work and have supported our
endeavors throughout many stages of development. While it
can be challenging to find investors that align with the
mission and values, when this happens the reward is
plentiful. To have such strong supporters and access to a
network of talented individuals willing to provide guidance
and expertise is invaluable and has helped us position
CathVision to maximize commercial and strategic
partnership opportunities.
Another inherent challenge of growth is building the
CathVision team. Our company is led by passionate
innovators and strategic thinkers with entrepreneurial spirit
that drives our company forward. We're always looking to
add to that energy and dedication as we expand our team. It
can be challenging to find the right fit but it's necessary to
ensure our collaborative culture thrives as that is a key
component driving the innovation that leads to the
development of technology that is changing the paradigm in
cardiac arrhythmia treatment.
What advice would you like to give budding
entrepreneurs and enthusiasts who want to engage in
the medical devices sector?
The first ingredient is to be so motivated that you must
move forward despite any and all challenges. I think
motivation can come quite suddenly and it is often inspired
by others around you who achieve goals that you dream of.
This motivation will be key, as you initially think that you
are building a product over just a few years, and then learn
later that you are actually building a company that
commonly takes 10 years and encompasses much more than
just a product.
Be prepared to push on a high amount of fronts at the same
time. You will advance many tracks in parallel, and you will
initially feel more comfortable spending too much time on a
few things rather than spreading your time over many
things. It's an unreasonable job description to be a founder,
as you will not be able to do anything well enough in the
beginning. I advise budding entrepreneurs to deal with
intimidating tasks early on, such as user/customer
interviews, where you will inadvertently meet some sour
clinical users who think you are not ready yet. The cost of
not understanding your clinical need early will be manyfold
multiplied later. I advise entrepreneurs to ask others for
advice on how you define your market, price,
reimbursement, regulatory and any topics where you will
start with just a wild guess yourself.
How do you envision scaling the company's services and
operations in 2023 and beyond?
2023 has been a compelling year for CathVision as we've
focused on validating our ECGenius System. Our team
worked closely with electrophysiologists throughout the
world to fully understand how our technology is being used
to improve the diagnosis and treatment of complex cardiac
arrhythmias. Through these efforts, we heard first hand
from respected physicians about the importance of our
unique focus on signal quality and how this has enabled
physicians to improve treatment strategies.
In the final months of 2023 and throughout 2024, our efforts
will transition to focus on the commercial launch of our
ECGenius System with integrated AI algorithms to
facilitate electrogram interpretation and deliver
unprecedented levels of intelligent, automated analyses.
CathVision is the only company delivering this advanced,
technology solution, so we're ramping up our sales team to
support the full commercial launch while also continuing to
invest significantly in R&D that will bring additional
algorithms to the system in the future.
August 2023

Dynamic Oﬀerings
August 2023

Modern
Healthca
Mee ng the
Demands of
The healthcare landscape is rapidly evolving, driven
by technological advancements, patient
expectations, and the ever-expanding body of
medical knowledge. To thrive in this dynamic environment,
healthcare providers and organizations must embrace a
range of dynamic offerings that can help them effectively
meet modern healthcare demands.
Let's explore these dynamic offerings and how they are
shaping the future of healthcare in detail!
Telemedicine
Telemedicine has emerged as a revolutionary dynamic
offering in modern healthcare. It utilizes technology to
overcome geographical barriers and provide patients with
access to medical care regardless of their location. This
innovation has been particularly invaluable during the
COVID-19 pandemic when in-person visits became
challenging.
Telemedicine offers numerous benefits, such as improved
access to specialists, reduced patient travel time, and
increased convenience. Moreover, it allows healthcare
providers to reach a wider patient base, resulting in
enhanced healthcare delivery and, ultimately, better patient
outcomes.
Electronic Health Records (EHRs)
Electronic Health Records, or EHRs, have transformed how
healthcare providers manage and access patient
information. This dynamic offering digitizes patient data,
making it readily accessible to authorized personnel
anytime and anywhere.
EHRs enable a seamless flow of information among
healthcare professionals, leading to more coordinated and
efficient care. They reduce the risk of errors associated with
paper-based records, provide a comprehensive view of a
patient's medical history, and support evidence-based
decision-making. Furthermore, EHRs facilitate
communication between different healthcare facilities,
enhancing continuity of care for patients.
Artificial Intelligence (AI) and Machine Learning
Artificial intelligence and machine learning are among the
pioneers in healthcare innovation. These dynamic offerings
have the potential to revolutionize diagnostics and
August 2023

treatment planning. AI-powered algorithms can analyze
numerous medical data to assist healthcare professionals in
diagnosing diseases, predicting patient outcomes, and
personalizing treatment plans.
In addition, AI algorithms can detect abnormalities the
human eye may not know. They can also help predict
disease progression, allowing for early intervention and
better patient management. Additionally, AI-driven chatbots
and virtual assistants provide patient support and answer
common medical queries, reducing the burden on
healthcare staff.
Precision Medicine
Precision medicine recognizes that each patient is unique,
and medical treatments should be tailored to an individual's
genetic makeup, lifestyle, and environment. The
advancements in genomics and molecular biology have
made precision medicine a reality.
By analyzing a patient's genetic profile, healthcare
providers can identify specific genetic mutations or
variations that may influence their response to medications
and treatment protocols. This allows for the creation of
highly targeted therapies that are more effective and have
fewer side effects. Precision medicine is particularly
promising in the field of cancer treatment, where it has led
to significant advancements in therapy selection and
response prediction.
Wearable Health Devices
Wearable health devices like fitness trackers and
smartwatches have become ubiquitous in recent years.
These dynamic offerings empower individuals to take
charge of their health by monitoring various health metrics
in real time. From tracking steps and heart rate to
monitoring sleep patterns and blood pressure, these devices
provide valuable data that can be shared with healthcare
providers for a comprehensive view of a patient's health.
Moreover, wearable devices are increasingly being used to
detect and manage chronic conditions. For example,
continuous glucose monitoring devices can help diabetics
manage their blood sugar levels more effectively. As
technology advances, these devices are becoming more
sophisticated and capable of monitoring a wide range of
health parameters, enhancing their effectiveness in modern
healthcare.
Blockchain Technology
Data security and privacy are vital in healthcare. The
adoption of blockchain technology is a dynamic offering
that addresses these concerns. Blockchain, the fundamental
technology of cryptocurrencies like Bitcoin, provides a
secure and immutable ledger for healthcare data.
By using blockchain, healthcare organizations can ensure
the integrity and confidentiality of patient records. Patients
have more control over their health information, granting
access to healthcare providers as needed while maintaining
privacy. This technology can also streamline processes like
insurance claims processing and drug traceability, reducing
fraud and errors in healthcare transactions.
Data Analytics
The healthcare industry generates an enormous amount of
data daily. Dynamic offerings in data analytics harness this
wealth of information to derive meaningful insights. By
analyzing big data, healthcare organizations can identify
trends, predict disease outbreaks, optimize resource
allocation, and improve patient outcomes.
For instance, data analytics can help identify high-risk
patient populations, allowing for proactive interventions to
prevent complications and reduce healthcare costs. It can
also assist in predicting the demand for specific medical
services, enabling healthcare providers to allocate resources
efficiently.
In conclusion, modern healthcare is evolving rapidly, and
dynamic offerings are at the forefront of this
transformation. These innovations transform healthcare
delivery, improve patient outcomes, and enhance the overall
healthcare experience. Embracing these dynamic offerings
is essential for healthcare providers and organizations to
meet the demands of modern healthcare effectively and
provide the best possible care to patients in an ever-
changing landscape.
- Nisha Mehra
August 2023

In a world where cancer incidence continues to rise, the
urgency to transform its management into a survivable
journey has become more crucial than ever. In this
critical pursuit, iCellate Medical AB emerges as a game-
changer in the realm of personalized cancer diagnostics.
With an unwavering commitment to revolutionizing the
field, the company is at the forefront of medical technology,
paving the way for more effective detection and monitoring
of cancer.
Founded on the principle that every patient's journey is
unique, iCellate harnesses the power of advanced liquid
biopsy technology to provide unparalleled insights into
cancer progression. By leveraging the potential of
circulating tumor cells (CTCs), iCellate has developed an
innovative platform that enables precise and non-invasive
analysis at the cellular level.
With the company’s groundbreaking solutions, healthcare
professionals not only gain invaluable tools to optimize
treatment strategies and monitor therapeutic responses
tailored to each patient's individual profile, but also feel
empowered with unprecedented knowledge. This way, the
company is thus shaping the future of cancer care, offering
hope and improved outcomes to patients around the world.
In an interview with Insights Care, Pelle Redare, the CEO
of iCellate shares in depth about its groundbreaking
contributions towards personalized cancer diagnostics, thus
transforming the landscape of cancer management, making
survival a reality for more people.
Following are the excerpts from the interview.
While iCellate marks the beginning of my time in the
oncology space, my career in the medical device field began
decades ago. There is something so utterly personal about
working for the betterment of individuals’ lives. Diagnostic
development is a long journey, but I find endurance in the
possibility of making a personal impact.
iCellate strives to reduce cancer mortality through early
detection and actionable tumor profiling so that cancer can
be treated with precision. The earlier we can intervene in
the cancer lifecycle, and the more specifically we can target
the cancer cells – while sparing healthy ones – the more
likely we are to survive cancer. As cancer incidence rises
the key to its management is to make it survivable.
Give us an idea about the company’s services/products.
®
iCellate’s core technology, CellMate , detects circulating
tumor cells (CTCs) in a regular sample of blood. CTCs are
known for being the mechanism by which tumors
iCellate
Medical AB
Reducing Cancer Mortality Through Early
Detection & Actionable Cancer Profiling
August 2023

iCellate
strives to reduce
cancer mortality through
early detection and
actionable tumor proﬁling
so that cancer can be
treated with precision.
The earlier we can
intervene in the cancer
lifecycle, and the more
speciﬁcally we can
target the cancer cells –
while sparing healthy
ones – the more likely
we are to survive
cancer. As cancer
incidence rises the key
to its management
is to make
it survivable.
Pelle Redare
CEO
August 2023

metastasize, or migrate to other parts of the body, but CTCs
are even detectable before symptoms arise.
Our long-term goal is to implement our platform for early
cancer detection in high-risk groups and, if successful,
cancer screening in the general population. Our current
focus is to detect CTCs in patients who already have a
cancer diagnosis or suspicion of cancer, but whose tumors
require further profiling in order to select the most
appropriate treatment for the patient. Our ongoing dialogue
with clinical oncologists, patient organizations and the
pharmaceutical industry help inform which clinical
questions to tackle next.
The company’s guiding principle is Patient First. Afterall,
our mission to reduce cancer mortality is about prolonging
the lives of individuals. Developing and validating an early
detection or screening tool is a long journey with a high
burden of evidence. With a Patient First-mindset we build
endurance and drive to ultimately reach our goal.
care?
®
With our CTC platform, CellMate , we’re developing the
first liquid biopsy alternative for the detection of targetable
tumor antigens. Many of us are familiar with the promise of
and advancements in precision oncology, or the tailored
treatment of cancer patients based on their biomarker status.
The first wave of precision medicine for cancer patients
targets genomic biomarkers we call driver mutations.
Pharmaceutical pipelines are now filling up with new assets
that target protein biomarkers, for example tumor antigens.
The measurement of protein expression has historically
required a tissue biopsy, which is difficult to obtain in many
®
cancer types. CellMate offers multiplexed protein
expression analysis with a standard blood draw, expanding
diagnostic access to more patients.
What are some of the challenges that the company faces
when conducting its operations and how does it turn
them into opportunities for growth?
The early development years can feel like a chicken and
egg dilemma. Investors want to see clinical evidence, but a
lot of development work is required before generating
meaningful clinical data. Diagnostic development is
resource intensive and requires capital, so we need to
translate early development milestones into something that
shows early investors our technology is advancing. This has
forced us to be thoughtful of how we prioritize our
development work and utilize the resources we have –
lessons we’ll continue to draw upon as grow and advance.
What advice would you like to give to budding
entrepreneurs and enthusiasts who desire to engage into
Love what you do! It will take three times as long as you
think and be five times as expensive. Know what motivates
you and why you’re doing what you’re doing. Talk about it!
Revisit your mission statement at every company meeting.
Ask new team members what it means to them and share
what it means to you. This is hard work and reminders and
new perspectives help.
How do you envision scaling the company’s services and
This year our focus is on generating clinical data to secure
commercial partnerships with pharmaceutical companies
and attract new investment. When commercial volume
demands, we’ll prioritize operational scale-up, throughput
and automation.
August 2023

Subscribe Today
Stay in Touch.
Subscribe to Insightscare Get Insights Care
Magazine in print, & digital on
www.insightscare.com
Corporate Ofﬁce
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin,OH 43017, United States
Phone - (614)-602 - 1754,(302)-319-9947
For Subscription : www.insightscare.com
Cheque should be drawn in favor of :
INSIGHTS SUCCESS MEDIA TECH LLC
www.insightscare.com

Scandinavian
ChemoTech
The Impact of Oncology Technology on Patient Care
uman intelligence has reached a stage where we
Hare developing technology to treat diseases we
thought were not curable. Today oncology
treatment allows companies to create digital health
platforms to support patients during their cancer treatment
journey. Oncology technology is playing a crucial role in
advancing cancer treatment, promoting early detection,
enhancing personalized care, and improving the quality of
life for cancer patients.
Striving to make a significant contribution to the fight
against cancer, Scandinavian ChemoTech is ultimately
improving patient outcomes and advancing the field of
oncology. Along with other oncology institutions, the team
at Scandinavian is driving the progress and implementation
of TSE, fostering advancements in cancer care.
Thus in this search of Europe's Most Innovative Medical
Device Companies, we at Insights Care interviewed
Mohan Frick & Dr. Suhail Mufti to know how they are
using these technologies and making better place for
everyone.
I started my medical device career at 15 -18 as a school
vacation worker. At 27, I became the International
Marketing Manager for the same company, ARJO, and
became a member of the Management Group. In 2011 I
shifted into Oncology, an area and industry where I can
combine making the work a better place by helping people
in need and generating income for the company, its
shareholders and myself.
My hypothesis was that the destruction itself could be the
reason why many therapies are not successful. I went to a
professor in Radio Physics. Prof. em. Bertil Persson from
Lund University who agreed with my idea and even had
some older research that could be used in the development
of the Tumour Specific Electroporation™ or TSE as its
called now.
TSE
Scandinavian ChemoTech specializes in the development
and innovation of medical devices for the treatment of solid
tumours. Tumour-Specific Electroporation (TSE) developed
by ChemoTech is an innovative technique that delivers
targeted and multi-directional electrical pulses to enhance
the permeability of cancer cell membranes, allowing for a
more effective intracellular drug concentration with an
additional favourable effect on the tumour
microenvironment including immune modulation.
Ÿ It's a therapy why we use Dynamic and Tumor adapted
electrical pulses to generate small openings in tumor
cells through which anti-cancer drugs can enter and
Antigens can leak.
Ÿ The uptake of some drugs are more than 1000 times
higher with TSE and starts an apoptosis process without
creating quick destruction.
Ÿ The Antigens awakens the immune system
Ÿ Its portable laptop designs, with No need for change of
infrastructure
Ÿ Quick and effective. Each treatment takes max 25-30
min and needs to be repeated 2-5 times.
Ÿ No reported side effects related to TSE
August 2023

Ÿ IT works for both Human and Animals (Dogs, Cats and
Horses).
When developing an innovation or any product, its
important to identify your target groups and the problem
you wish to solve and develop a solution and packaging it
according to your clients' needs.
The largest cancer burden and mortalities are not in USA
and EU; it comes from India, Asia and Africa today. Their
largest needs are to get cost-efficient therapies that do not
Mohan Frick
CEO
Scandinavian ChemoTech
ChemoTech leverages
functionality for future AI
tools to develop treatment
algorithms, enabling personalized
medicine approaches that
incorporate immunotherapy,
radiotherapy, and other emerging
therapeutics. This integration of
AI helps optimize treatment
plans for individual patients
based on their unique
characteristics and needs.
only work in earlier stages of the disease but also work
when treatment resistance has accorded.
Therefore, our first goal for TSE was to be a solution for
Superficial tumors that can be removed by surgery, neither
responsive to Chemotherapy nor where radiotherapy has
failed.
The current needs in India alone are several 100 of
thousand of patients annually. That's why the initial market
focus for Human Care is Primary in India. For Animal care,
vets globally are desperately looking for new technologies
and therapies that work for superficial tumors that can't be
removed by surgical procedures and do not generate
destruction and harm
August 2023

ChemoTech's primary focus is on addressing the healthcare
challenges posed by head and neck cancer, advanced breast
cancer, and gynaecological cancers, with a particular
emphasis on the Indian market, where these cancers have a
significant burden.
The process of innovating medical devices at
ChemoTech involves several key steps:
Ÿ Research and Development: ChemoTech invests in
extensive research and development efforts to identify
the true potential of Tumour Specific Electroporation
(TSE) delivered using IQwave™, not only in the late-
stage palliative care setting but also in the earlier
treatment paradigms with curative intent. ChemoTech
focuses on investing in research and development to
address the unique challenges of treating deeper
tumours, specifically targeting pancreaticobiliary
tumours.
Ÿ Clinical Trials and Regulatory Compliance:
ChemoTech conducts rigorous clinical studies to
evaluate the safety and effectiveness of TSE in solid
tumours. Real-life data analysis and real-time remote
monitoring of the clinical data help to evaluate multiple
indications and combinations of therapeutics along with
TSE. Strict adherence to applicable regulatory standards
and guidelines is practiced to ensure compliance with
relevant healthcare regulations.
Ÿ Collaboration and Partnerships: ChemoTech
collaborates with oncologists, researchers, and medical
institutions to gain insights and expertise in the field.
ChemoTech welcomes partnerships to accelerate the
development and adoption of TSE for deeper tumours
including the innovative minimally invasive robotic
approaches for deeper tumours.
company is built and what its mission is?
Our vision is to develop therapies for tomorrow and make
them accessible to cancer patients where other treatments –
for financial or medical reasons – are not available or where
the side effects are too severe. To achieve this, our strategy
is to further develop our technology to make it more
effective, easier to use, better adapted to clinical
environments and suitable for treatment of a wider
spectrum of illnesses and conditions.
What role does technology play in facilitating the
innovation of medical devices at the company?
Technology is a vital component in ChemoTech's
innovative development of TSE for solid tumors, playing a
pivotal role in advancing cancer treatment. ChemoTech
leverages functionality for future AI tools to develop
treatment algorithms, enabling personalized medicine
approaches that incorporate immunotherapy, radiotherapy,
and other emerging therapeutics. This integration of AI
helps optimize treatment plans for individual patients based
on their unique characteristics and needs.
Moreover, ChemoTech's TSE is not only effective in
enhancing drug absorption through electrical pulses but also
competent in delivering gene therapy. This is achieved
through plasmid transfer, facilitating the introduction of
therapeutic genes into the targeted cells. By utilizing this
approach, ChemoTech aims to further enhance the efficacy
of treatments and explore new avenues in cancer therapy.
Through its dedication to technology-driven innovation,
ChemoTech strives to revolutionize cancer care, tailoring
treatment strategies to specific tumor types, and maximizing
the potential of emerging therapies, ultimately improving
patient outcomes and advancing the field of oncology.
care?
ChemoTech's pioneering development of TSE represents a
significant advancement in the treatment of solid tumors,
offering a safe and effective approach that maximizes the
impact of Chemotherapy, reduces the required systemic
dose, and enhances the efficacy of immunotherapy and
August 2023

It normally takes lots of time and is very costly. Sweden
and India have entered into a bilateral healthcare
collaboration agreement for healthcare exchange.
Chemotech has been selected to be technology partner to
one of the initiatives where TSE is now undergoing a
clinical trial sponsored by an Innovation center at AIIMS
Jodhpur, one of the larger University hospitals in India.
They are establishing a standard TSE protocol for Head &
Neck cancer in India. (Potential to treat more than 100,000
new patients per year)
Do not think that you will find a shortcut to quick success. I
never heard of that! Be realistic and ensure funding for 3
years each time. Try to think outside the box and don't want
others do without making our own analysis.
New medical solutions should be smaller and more cost-
efficient than the existing ones. Government and private
Reimbursement will most probably put pressure on the
economic impact.
For Human Care, we will continue to focus on India. With a
recent potential to be the first treatment alternative for
superficial tumors in India, several thousands of patients we
have with our relationship with government health care
potential to become a Unicorn only on Head and Neck- and
Breast Cancer in India Alone. IQwave™ TSE
We see the same Unicorn potential in our Animal Care
division, where we already are supplying vetIQure™ TSE
technology to most of the largest global enterprises in
Veterinary Care with a potential to install hundreds of
devices in next years to come as our presents clients
collectively operate several thousands of clinics in EU and
North America.
Each IQwave™ or vetIQure™ device generates
approximately USD 20,000 to 70,000 annual income from
treatment kits, based on only treating 50 patients per year.
After TSE becomes standard therapy, the clinics will
probably reach at least 100-200 treatments per year.
radiotherapy. TSE has emerged as an innovative solution to
safely target deep-seated tumors, increasing the potential
for curative outcomes in these challenging cases. Ongoing
collaborative efforts between ChemoTech and leading
oncology institutions worldwide are driving the progress
and implementation of TSE, fostering advancements in
cancer care.
In the rapidly evolving landscape of cancer treatment, the
cost of therapies continues to rise. ChemoTech's TSE
provides an efficacious and cost-effective solution to
address this challenge. By leveraging TSE, healthcare
providers can optimize treatment outcomes while
minimizing the financial burden on patients and healthcare
systems. This approach demonstrates the potential to
revolutionize cancer care, providing a tailored and
economically viable option for the management of solid
tumors.
What are some of the challenges the company faces
when conducting its operations and how does it turn
them into growth opportunities?
Continually generating supporting clinical data is always
challenging, especially in Sweden where hundreds of
innovative companies compete on the few existing patients.
Dr. Suhail Mufti
Medical Director
Scandinavian ChemoTech
August 2023

Safetyand
Ef cacy
in the Healthcare
Industry
he healthcare industry is undeniably one of the most
Tcritical sectors, impacting the lives and well-being
of individuals worldwide. Within this vast and
intricate ecosystem, two fundamental pillars stand tall:
safety and eﬃcacy. These principles are the cornerstones of
high-quality healthcare, ensuring that patients receive the
best possible care while minimizing risks and maximizing
positive outcomes.
Safety, The Bedrock of Quality Healthcare
Safety in healthcare encompasses a wide range of aspects,
all aimed at protecting patients from physical,
psychological, or emotional harm. This multifaceted
approach to safety is essential to earn and maintain the trust
of patients and the community at large. Here are some
critical components of safety in healthcare:
Ÿ Patient Safety
Patient safety is paramount and encompasses various
elements. It starts with preventing medical errors, such as
administering the wrong medication or performing the
incorrect procedure. Robust systems and protocols must be
in place to reduce these incidents, ensuring patients are not
harmed due to avoidable mistakes.
Ÿ Infection Control
Infection control measures are vital, especially in healthcare
settings. Preventing the spread of infections within hospitals
and other healthcare facilities is critical to safeguarding
patients and healthcare workers.
Ÿ Medication Safety
Medication errors are among the most common medical
mistakes. Safeguarding against them requires meticulous
attention to detail, unambiguous labeling, proper
administration protocols, and patient education about their
medications.
August 2023

August 2023

Ÿ Equipment Safety
The proper functioning and maintenance of medical
equipment, from diagnostic tools to surgical instruments,
are non-negotiable safety aspects. Malfunctioning
equipment can lead to serious harm.
Ÿ Staff Training and Competency
Healthcare providers must receive comprehensive training
and maintain high levels of competency. Continuing
education ensures they stay up-to-date with the latest
medical advances and best practices.
Ÿ Transparency and Open Communication
Open communication with patients and their families is
essential. Healthcare providers must be transparent about
the risks, benefits, and potential complications of
treatments, enabling patients to make informed decisions
about their care.
Efficacy, Maximizing Positive Outcomes
While safety focuses on minimizing harm, efficacy is all
about maximizing the benefits of healthcare interventions. It
is not enough for healthcare to merely avoid causing harm;
it must actively strive to improve the health and well-being
of patients. Here are the key components of efficacy in
healthcare:
Ÿ Evidence-Based Practice
Healthcare decisions and interventions should be based on
rigorous scientific evidence. The practice of evidence-based
medicine ensures that treatments are not only safe but also
effective in achieving the desired outcomes.
Ÿ Patient-Centered Care
Efficacy extends beyond medical procedures and
treatments. It includes considering the individual needs,
preferences, and values of patients. A patient-centered
approach empowers individuals to participate in their
healthcare decisions actively.
Ÿ Timeliness and Access
Efficient healthcare delivery is crucial. Timely access to
care can be a matter of life and death. Reducing waiting
times for consultations, tests, and treatments is essential for
efficacy.
Ÿ Monitoring and Assessment
Regularly monitoring and assessing patients' progress is
essential to ensure effective treatments. If a particular
approach is not yielding the expected results, adjustments
can be made on time.
Ÿ Innovation and Research
The healthcare industry is continually evolving, thanks to
ongoing research and innovation. Efficacy depends on
embracing new technologies and treatment modalities that
have been proven to improve patient outcomes.
The Synergy of Safety and Efficacy
Safety and efficacy in healthcare are not opposing forces
but complementary principles that work together to provide
the highest quality care. For instance, a surgical procedure
may be highly effective in treating a condition but must also
be conducted safely to prevent complications and adverse
events.
Furthermore, the pursuit of safety and efficacy is a
continuous process. Healthcare providers and organizations
must commit to ongoing quality improvement initiatives
driven by data and feedback from patients and staff. These
initiatives help identify areas for improvement and refine
practices to ensure that both safety and efficacy are
maximized.
The Imperative of Quality Healthcare
There can be no compromise regarding safety and efficacy
in the healthcare industry. These twin pillars are the
foundation for trust, credibility, and high-quality care.
Patients rightly expect healthcare providers and
organizations to prioritize their well-being and continually
strive to improve outcomes while minimizing risks.
Pursuing safety and efficacy is not a one-time endeavor but
an ongoing commitment that requires dedication, education,
and innovation. By continually striving to enhance the
safety and efficacy of healthcare, the industry can fulfill its
noble mission of improving and preserving the health and
well-being of individuals and communities worldwide.
- Nisha Mehra
August 2023

Enhancing Independence
for Physical Disabilities
n this effort of improving the quality of life and
Iproviding independence to millions of individuals
worldwide, assistive technologies work to transform
the lives of people. According to the UN, by 2050, the
number of people aged 60 and above will reach 2.1 billion,
representing 21% of the world's population. This shift
underscores the importance of developing innovative
assistive technologies, improving the lives of those with
physical disabilities is bound to grow even further.
With one such inspiration, The Swedish Assistive
Technology Group called Hjälpmedelsteknik Sverige in
Swedish is improving the quality of life for the world's
aging population by providing reliable assistive aids and
giving them the ability to live to their fullest.
This is why we at Insights Care featured in its upcoming
edition of Europe's Most Innovative Medical Device
Companies, where we interviewed the team at The
Assistive Technology Group from Sweden —
Hjälpmedelsteknik Sverige to know how the company
tackles all the challenges from its foundation.
People live longer and face challenges that need to be met
in order to maintain an active and independent lifestyle
throughout life's changes. That is our inspiration and this is
the journey of the Swedish Assistive Technology Group and
Hjälpmedelsteknik Sverige.
Our inspiration is to improve the quality of life for the
world's aging population by providing reliable, innovative
and life stimulating assistive aids that optimize every
individual's independence and ability to live life to its
fullest regardless of what challenges every person has to
tackle.
Hjälpmedelsteknik Sverige AB was founded in 1999 by
Jonas Christensson and Christer Magnusson, both with
an extensive background in the area of assistive technology.
It is one of Sweden's oldest private companies in the
assistive technology sector. The company started as a
provider of technical services to the public sector in
Southern Sweden. Ten years later the two founders
recognized that it was necessary to broaden the company
activities in order to grow and develop. They decided to
take the lead within the private sector of the assistive
technology market in Sweden.
Contacts were established with an international consulting
company which led to a contact with Lars Akerman, an
internationally experienced business developer with a
background in many different industries in Eastern and
Western Europe, North America and the Far East.
The company started to expand its activities and the first
steps were taken to develop new activity areas. One of these
was retail and the private market of assistive technology,
which until then had been non-existing as the public sector
in Sweden provided all basic needs within this area. As the
population was aging and the financial resources in the
already highly taxed country of Sweden were under hard
pressure - and are expected to continue to be more limited
than in earlier decades – a development of the private sector
was likely.
Aging is a natural process that – even though we live better
and longer – causes problems in different ways – reduced
mobility, vision, hearing, balance, muscle strength and
much more. Noone wants to go through this, but most of us
will and the decision was taken by Jonas, Christer and Lars
to take on the challenge to become the leaders within this
area, starting in Sweden.
Assistive Technology
The Swedish
Group
August 2023

In order to be successful within this area it was of critical
importance to develop international contacts and
cooperation with leading researchers, developers and
manufacturers globally, to become involved in
manufacturing and in research and development of new
technology.
The development started and the ﬁrst retail stores opened
with one focus – to make life easier and to improve the
quality of life for the aging population.
In 2014 Lars Akerman was appointed Managing Director.
Close relations were established with industry developers
ranging from internationally established and leading
companies like Resmed, Philips, Invacare, Heartway,
Himolla, Sunrise Medical, Care of Sweden and many others
to new, innovative developers and manufacturers like Rollz
International, e-ability, Life Mobility and Human Protection
from the Netherlands, Saljol from Germany, MyAddon and
Entusia from Belgium, and Strongback from Switzerland.
The manufacturing company JCM Elektronik - which had
developed and manufactured a unique mobility platform –
the AKKA - for children and adults with neurological and
multidisabilities – was acquired in 2014 and the year after
Hjälpmedelsteknik became a member of a European
consortium to develop the world's ﬁrst exo-skeleton for
elderly persons. The consortium consisted of 3 European
universities, a hardware company which among other things
supplied the international space station and a software
company developing software for companies like Sony –
and the Swedish Hjälpmedelsteknik. The R & D company
Euro Wearable Technology was founded and the small
Hjälpmedelsteknik group continued to grow and develop.
The cooperation opened the door for the company to many
internationally leading developers and suppliers and
The product
development process is
always based on end-
user needs.The
solutions must be
reliable and easy to
understand for the end
user.They must always
be cost-ef cient. All
products must have a
high quality that makes
them last long.
Lars Akerman
CEO
Assistive Technology Group
August 2023

strengthened the company's involvement in product
development.
In 2017 one of the two original founders – Christer
Magnusson – sadly passed away and Lars Akerman decided
to join the company as equal partner to Jonas Christensson.
The company board was strengthened and Dr Stefan Gram -
previous group physician for the Tetra Pak group - was
appointed Chief Medical Advisor.
As a result of the close relations the company today
represents its international manufacturers – often in all the
Nordic countries of Sweden, Denmark, Norway, Finland
and Iceland - and we take active part in the product
development that beneﬁts consumers all over the world.
The company's retail activities in Sweden expanded to 6
retail stores, a franchise system was developed and a
decision to establish 40 physical retail stores and the
market's leading industry e-commerce platform was taken.
In 2020 the decision was taken to divide the group into four
divisions under the name of the Assistive Technology
Group:
B2B – Hjälpmedelsteknik Sverige AB - sales to
distributors, retailers and the public sector in all Nordic
countries
B2C – Keep on Retail AB – sales to consumers through
own and franchised stores and through an industry-leading
platform - keepon.se.
Manufacturing – JCM Elektronik AB – development and
manufacturing of the AKKA system (sold in most countries
in Europe and in Japan, Hong Kong and Singapore).
R & D – Euro Wearable Technology
Ÿ Healthcare needs and solutions
Maintained independence is one of the most critical
tasks for every person as we age. It has a tremendous
impact on the quality of life for every individual, why
solutions within this area are crucial. It covers a number
of areas ranging from mobility, strength, balance,
incontinence, communication, social life and much
more. To ﬁnd new, innovative and reliable solutions in
these areas remains our focus and we are proud that this
has brought us to become one of Europe's most
innovative medical device companies of 2023.
The product development process involves our product
development team, medical advisors, researchers,
manufacturers and end users. The process is sometimes
very long and sometimes we can bring a product to market
within a few months.
August 2023

The product development process is always based on end-
user needs. The solutions must be reliable and easy to
understand for the end user. They must always be cost-
efficient. All products must have a high quality that makes
them last long. This is important from a financial,
environmental and operational efficiency standpoint.
Our operation is built on important core values that can be
found in every imployee and every aspect of the company's
activity:
Knowledge, quality, integrity, honesty, efficiency, service
and reliability (in production, sales, after sales service in
products as well as employees, policies, guidelines and
organization). Company motto: Nothing is impossible.
What are some of the challenges that the company faces
when conducting its operations and how does it turns
them into opportunities for growth?
Ÿ Development is costly and requires funding to remain at
the forefront.
Ÿ Lack of future vision among banks and investors with
regards to our industry is quite common compared to
sexier and more high tech industries.
Ÿ The cross over between the public and private sector
within the assistive technology industry.
Be patient and long term focused.
It is an industry for the future, moves slowly but only goes
in one direction as the world's population is aging. It is not
a question of if, but when.
Always think of the benefit of a product or solution, what
impact it will have on a person's life rather than the product
itself.
Get to know the end user the solution is for, his/her ability
to use it, how it makes the user feel, how it impacts other
people and the environment.
Think globally but respect locally.
Ÿ Create a positive, dynamic, friendly, helpful, ambitious
and fun work environment.
Ÿ Turnover. The ambition is to profitably develop the
company's B2B business by 8-10 times current sales and
the B2C in Sweden by 8-10 times within the next 5
years as the industry structure is changing.
Ÿ Product development. The ambition is to launch the
next generation of the AKKA system to the market and
to launch one new unique product/solution per year over
the next 5 years.
Ÿ Organization. Our ambition is to maintain our fantastic
employees, the wonderful spirit and atmosphere within
the company, continue to improve knowledge and
increase our experience, maintain or further strengthen
the relations with our international partners and to focus
on being a company with high ambitions with a healthy
respect for the challenges.
August 2023

Helping Technology
Technology
Technology
Work With You &
For You
For You
For You

Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdf

Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdf

Recommended

Recommended

More Related Content

Similar to Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdf

Similar to Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdf (20)

More from insightscare

More from insightscare (20)

Recently uploaded

Recently uploaded (20)

Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdf